Business Context and Reporting Period
This Form 8-K was filed by Barinthus Biotherapeutics Plc. on August 24, 2026. The filing announces the Company's intent to delist its American Depositary Shares (ADSs) from The Nasdaq Global Market following the expected effectiveness of a Scheme of Arrangement on September 3, 2026. This action is part of a proposed combination with Clywedog Therapeutics, Inc., pursuant to a Merger Agreement dated September 29, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and transactional events rather than financial performance results.
Material Changes and Transaction Details
- Delisting and Deregistration: The Company notified Nasdaq of its intent to withdraw the listing of its ADSs. Upon effectiveness of the Form 25, the Company intends to file a Form 15 to suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
- Trading Halt: Trading of ADSs on Nasdaq is expected to halt prior to the market opening on September 3, 2026.
- Post-Merger Structure: Following the transaction, the subsidiary Topco will be renamed "Clywedog Therapeutics Holdings, Inc." and its common stock will list on Nasdaq under the ticker symbol "CLYD."
- Exchange Ratio Determination: The Board of Directors determined the Scheme Exchange Ratio is 0.111. This ratio ensures the price of Topco's common stock issued in exchange satisfies Nasdaq's minimum price listing requirements.
- Legal Proceedings: The application for the transactions is scheduled to be heard by a High Court Judge in London on September 1, 2026.
Outlook, Risks, and Management Commentary
Management issued a press release on August 24, 2026, providing an update on the proposed combination. The filing includes extensive forward-looking statements regarding the timing of the Scheme, the suspension of trading, and the determination of the Merger Exchange Ratio.
Key risks identified include:
- The possibility that the proposed transaction may not be completed in a timely manner or at all.
- Unexpected costs, liabilities, or delays associated with the transaction.
- Diversion of management's attention from ongoing business operations.
- Risks related to the Company's ability to fund operations and access capital.
- Uncertainty regarding the realization of anticipated benefits from the corporate restructuring.
Investor Verification Checklist
- Verify the final outcome of the High Court hearing scheduled for September 1, 2026, in London.
- Confirm the exact timing of the trading halt for ADSs on September 3, 2026.
- Monitor the filing of Form 25 with the SEC to confirm the official delisting and deregistration of ADSs.
- Review the final Merger Exchange Ratio once determined immediately prior to the closing of the merger.
- Check for the listing of the new entity, Clywedog Therapeutics Holdings, Inc., under the ticker "CLYD" on Nasdaq.